KR20120081723A - Monoclonal antibody to specific monkey cd43 and a hybridoma producing the same - Google Patents

Abstract

PURPOSE: A high affinity monoclonal antibody anti-monkey CD43 antibody and a hybridoma producing the same are provided to recognize monkey-specific CD43 antigen with high affinity and to enhance T cell activation. CONSTITUTION: An anti-monkey CD43 monoclonal antibody is specific to CD43 antigen isolated from a monkey. The CD43 antibody contains a variable region of heavy chain having an amino acid of sequence number 1 and a variable region of light chain having an amino acid of sequence number 2. The monoclonal antibody is produced by a hydridoma(deposit number KCLRF-BP-00231). A composition for treating CD43+T cell-mediated or related diseases contains the CD43 antibody or a variant thereof.

Description

Monoclonal antibody specific for monkey CD433 and fusion cell line producing it {Monoclonal antibody to specific monkey CD43 and a hybridoma producing the same}

The present invention relates to a high affinity monoclonal anti monkey CD4 antibody obtained using peripheral blood mononuclear cell (PBMC) cells isolated directly from the blood of monkeys and to fusion cell lines producing the same.

Non-human primates are roughly divided into apes and monkeys. About 30 kinds of monkeys are used as experimental animals, and monkeys widely used around the world include Macaca monkeys such as Rhesus monkey, Cynomolgus monkey, Baboon monkey and Common marmoset. Numerous studies have been reported around Rhesus monkeys. Currently, there is a boom in research using primates, such as research on AIDS, brain diseases, gene therapy using monkeys, and research on artificial organs, such as cross-organ transplantation (Biotechnology Policy Research Center, 27-62009-09-). 01, Biozine, 2004-06-17). However, in order to succeed, it is important to first understand the monkey's immune system and establish analytical methods. To this end, the production of monkey specific antibodies essential for the analysis and function of each immune cell should be preceded. As a method of detecting CD43 + T cells, methods such as FACS analysis, immunohistochemistry, and immunofluoresce are generally performed. All of them develop antibodies that specifically recognize the CD43 antigen. Is asking. However, no antibody is currently available that recognizes the Rhesus monkey CD43 antigen. Since there is no anti-human CD43 antibody that cross-reacts with the monkey CD43 antibody, there is an urgent need to develop an antibody that specifically recognizes only the monkey CD43 antigen.

The present inventors have recognized the above problems and needs, and in order to develop an anti-monkey CD43 antibody having high affinity for monkey CD43 antigen, we recognize monkey CD43 antigen by directly isolating PBMC cells of Rhesus monkey and immunizing them with mice. The present invention was completed by screening a fusion cell line capable of producing an antibody, and discovering that the antibody can detect CD43T cells or use as an adjuvant for treating cancer cells.

It is therefore an object of the present invention to provide anti-monkey CD43 monoclonal antibodies specific for the CD43 antigen.

Another object of the present invention is to provide a fusion cell line that produces anti-monkey CD43 monoclonal antibodies specific for the CD43 antigen.

Another object of the present invention to provide a composition for the treatment of diseases associated with CD43 ⁺ T cells.

In order to solve the above problems, the present invention provides anti-monkey CD43 monoclonal antibodies specific for CD43 antigen isolated from monkeys.

In the above antibody, the variable region of the heavy chain of the antibody is represented by SEQ ID NO: 1, and the variable region of the light chain is preferably made of an amino acid represented by SEQ ID NO: 2.

In addition, the monoclonal antibody can be produced by a fusion cell line with accession number KCLRF-BP-00231.

The present invention also provides a fusion cell line for producing the monoclonal antibody.

Preferably, the fusion cell line has an accession number of KCLRF-BP-00231.

In addition, the present invention may be mediated by, CD43 ⁺ T cells comprising the monoclonal antibody or its variations, there is provided a composition for the treatment of diseases which are associated with the CD43 ⁺ T cells.

The disease includes a disease caused by cancer or viral infection.

The anti-monkey CD43 antibody according to the present invention can recognize monkey-specific CD43 antigen with high affinity, and can be usefully used for the treatment of diseases caused by cancer or viruses by enhancing the activity of T cells.

Figure 1 shows a schematic diagram of the manufacturing process of a monoclonal antibody having specificity for monkey immune cell CD43 antigen.
FIG. 2 shows immunoprecipitation (IP) using commercially available aCD43 antibodies (clone: YG-5, DFT-1) and monoclonal anti-monkey CD43 antibodies of the present invention to characterize monkey CD43 antibodies of the present invention. ) And the results of western blot (WB) method is shown in cross-section (1) Antibody IP / YG5 WB 2) CEM7 lysate / Antibody WB 3) YG5 IP / Antibody WB 4) DFT1 IP / present invention Antibody WB).
-CEM7: human T cell, lysate
-YG5 IP: anti-CD43 antibody
-DFT1: anti-CD43 antibody
Figure 3 shows the genetic information for the CDRs region for determining the affinity of the cDNA base sequence of the high-affinity monoclonal anti-monkey CD43 antibody obtained through the present invention divided into the variable region of the heavy chain and light chain. CDR portions on each amino acid sequence are shown in red letters. VH means heavy chain variable region, VL means light chain variable region.
Figure 4 is treated with mouse Igg (1ug / well), CTLA4-Ig (0.5ug / well) and the anti-monkey CD43 antibody of the present invention, showing the degree of increased T cell activity.
5 is a graph showing the CD43 antibody as an agonistic antibody, mIgg (1ug / well), 30ul of aCD43 hybridoma culture solution, purified aCD43 antibody (0.5ug / well) and the result of measuring the amount of radioactivity using a beta-counter .

The present invention relates to anti-monkey CD43 monoclonal antibodies specific for the CD43 antigen isolated from monkeys.

More specifically, the present invention relates to a monoclonal antibody that specifically recognizes the monkey CD43 antigen secreted by the fusion cell line of accession number KCLRF-BP-00231.

As used herein, the term “monoclonal antibody” refers to a highly specific antibody directed against a single antigenic site (epitope) as is known in the art. Typically, unlike polyclonal antibodies that include different antibodies directed against different epitopes, monoclonal antibodies are directed against a single epitope on the antigen. Monoclonal antibodies have the advantage of improving the selectivity and specificity of diagnostic and analytical assays that use antigen-antibody binding, and can also be produced by hybridoma culture or phage display methods. Has the advantage of not being contaminated by other immunoglobulins.

The monoclonal antibody of the present invention may be used without purification, but may be purified by necessity according to a method commonly used in the art. Examples of such purification methods include dialysis, salt precipitation, ion exchange chromatography, size exclusion chromatography, affinity chromatography, and the like, but the antibody purification method of the present invention is not limited by the above examples.

In addition, the monoclonal antibody of the present invention recognizes a specific epitope of the antigen and has the binding properties of the antigen-antibody complex, as well as the complete form having two full-length light chains and two full-length heavy chains, as well as the antibody molecule. Include functional fragments.

A functional fragment of an antibody molecule refers to a fragment having at least antigen binding function and may be Fab, F (ab '), F (ab') 2, Fv, and the like.

In one embodiment of the present invention, in order to obtain monoclonal antibodies, PBMCs are isolated from the blood of Rheus monkeys, and the splenocytes isolated after immunoinjection into the mouse abdominal cavity are fused with rat myeloma cells. Monoclonal anti-monkey monkey CD43 antibodies can be isolated and purified.

The monoclonal antibody of the present invention may be a monoclonal antibody comprising both a light chain variable region and a heavy chain variable region. The variable regions of the light and heavy chains of the antibodies of the invention comprise three multivariable regions called "complementarity-determining resions (CDRs)" and four "framework regions (FRs)". The CDRs mainly serve to bind to epitopes of antigens. The CDRs of each chain are typically called CDR1, CDR2, CDR3 sequentially from the N-terminus and are also identified by the chain in which the particular CDR is located. On the other hand, the monoclonal antibody of the present invention can be prepared by conjugating the structural region (FR) of a known therapeutic antibody to a complementarity determining region (CDR). The present invention provides a nucleotide sequence of the CDRs for the variable region of the heavy and light chain of the monoclonal antibody.

By recognizing a specific epitope of the antigen and forming the antigen-antibody complex, the heavy and heavy chain variable regions, particularly the complementarity determining region (CDR), determine the affinity of the complex, thus cloning the existing monoclonal antibody genes. Gene sequencing of variable regions of the heavy and light chains of the antibody can be analyzed. To analyze the nucleotide sequence, RNA can be extracted from the fusion cell line and subjected to RT-PCR using Mouse Ig-Primer set (Novagen, CA, USA).

The "PCR" is well known in the art using a target nucleic acid as a template, using a primer specific for the target nucleic acid, amplifying the target nucleic acid by repeating the process of denaturation, annealing and extension reaction it means. The "RTPCR" is a reverse transcriptase polymerase chain reaction, a technique of synthesizing a corresponding cDNA (complementary DNA) using RNA of a specific site as a template and then using the PCR amplification. The experimental procedure is divided into the process of preparing cDNA from RNA using reverse transcriptase and the process of amplifying a specific site using cDNA. The amplification process using cDNA is the same as the amplification process of the above PCR. The base sequence of the monoclonal antibody is characterized in that the variable region of the heavy chain (light chain) and light chain (light chain) of the antibody comprises the amino acid sequence shown in SEQ ID NO: 1,2.

Another aspect of the present invention relates to a fusion cell line producing the monoclonal antibody. In the present invention, the term 'hybridoma' refers to a cell obtained by fusing B lymphocytes that produce antibodies and myeloma cancer cells, and myeloma cells are transformed cells, which have the advantage of being cultured for a long time in a culture dish. For example, the isolation of myeloma hybridomas that produce only one antibody means that a large amount of monoclonal antibodies can be easily obtained. In one embodiment of the present invention, CD43T cells are purely isolated from the blood of Rheus monkey, and the splenocytes isolated after immuno-injection into the mouse abdominal cavity are fused with rat myeloma cells to monoclonal anti-monkey CD43 antibody. Obtained fusion cell lines were produced. This was finally screened for fusion cell lines producing antibodies with high affinity for CD43 ⁺ T cells through limit dilution culture.

A fusion cell line secreting monoclonal antibodies having the above characteristics was issued to the Korean Cell Line Bank (KCLB) on April 5, 2010, in accordance with the provisions of the Budapest Treaty on the International Approval of Microbial Deposits in Patent Procedures. It was deposited as Accession No. KCLRF-BP-00231.

The present invention also relates to a method for separating CD43 + T cells using a high affinity for monkey CD43 T cells of the anti-monkey CD43 monoclonal antibody obtained in the above fusion cell line. Since the antibody of the present invention shows high affinity for monkey CD43 antigen, it is excellent for analysis of CD43 ⁺ T cells through flow cytometry, fluorescence immunoassay, immunohistostaining, etc., and can isolate CD43 ⁺ T cells with high efficiency.

The flow cytometry can analyze the characteristics of various cells by forming numerous cells in a single flow in a fluid column and measuring the size, structure and granularity of each cell while passing through a laser beam. It is a way. Very small amounts of fluorescent material can be recognized, allowing for high accuracy and sensitivity, and measuring or isolating a small subset of subtypes from a variety of mixed cell populations. The flow cytometry is a cell marker test such as leukemia marker test using a monoclonal antibody, growth cycle analysis according to the amount of DNA of the cell, reticulocyte count, neutrophil function test, anti-platelet antibody test and retinal platelet count test, tumor protein detection And other research purposes. By using the antibody of the present invention with superior affinity to antigen than conventional antibodies, CD43 ⁺ T cells can be isolated more accurately and efficiently.

The fluorescence immunoassay refers to a method of quantifying a specific biomolecule, measuring molecular weight, and determining a location of the molecule in a cell or tissue by using a characteristic of antibody and antigen binding.

In another aspect, the present invention the anti-monkey CD43 monoclonal antibody or or mediated by CD43 ⁺ T cells including the modifications thereof, the present invention relates to a composition for the treatment of diseases related to the CD43 ⁺ T cells. In addition, the above antibodies or modifications thereof can be used in all methods applied to the diagnosis of CD43T cell mediated diseases. More specifically, analysis of monkey CD43 antigen, quantitative and qualitative analysis of CD43T cells, and the like may be included.

Such modifications include the use of anti-CD43 antibodies for the production of all variants applied to depletion and inactivation of CD43 + T cells in vivo. More specifically, it refers to a variant by chemical conjugation to the CD43 antibody, or the genetic modification of the antibody and all the variants produced by using the cDNA base sequence information of the monoclonal antibody.

There are no limitations of chemical methods and chemical additives for the production of variants by chemical bonding, but specifically, single chain bacterial toxin (Pseudomonas exotoxin, diphtheria toxin), plant holotoxins (lysine class II ribosome inactivating protein) cell toxins such as ricin, abrin, mistletoe, lectin, moceccin, or hemitoxins (gelonin, saporin, pokeweed antiviral protein, class I ribosome inactivating proteins). Through variants. That is, the production of toxin fusion antibodies in which bacterial endotoxins and exotoxins, which are toxins, are bound to the Fc portion of the anti-monkey CD43 antibody by chemical and genetic methods.

Variant production by the genetic method includes all forms of single-chain, double-chain recombinant protein made using cDNA information and recombinant technology.

Or mediated by CD43 ⁺ T cells in the composition, the condition associated with CD43 ⁺ T cells include the diseases caused by cancer or a virus infection. The anti-monkey CD43 antibody or a variant thereof produced in the present invention can be used as an adjuvant. In one embodiment of the present invention, it was confirmed that the anti-monkey CD43 antibody produced in the present invention increased the amount of T cell activity more than other antibodies.

As used herein, the term "cancer" refers to a disease associated with cell death control, and refers to a disease caused by excessive proliferation of cells when a normal apoptotic balance is broken. These abnormally overproliferating cells sometimes invade surrounding tissues and organs to form masses and destroy or modify the normal structure of the body, which is called cancer. In general, the term "tumor" refers to a mass abnormally grown by autonomous overgrowth of body tissues, and may be classified into a benign tumor and a malignant tumor. Malignant tumors grow much faster than benign tumors, and metastasis occurs as they infiltrate surrounding tissues, thereby threatening life. Such malignant tumors are commonly referred to as 'cancer', and in the present invention, monoclonal antibodies can be used as an adjuvant to treat cancer.

Hereinafter, the present invention will be described in detail through examples. The following examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited by these examples according to the gist of the present invention to those skilled in the art. Will be self-evident.

Example  1: anti monkey CD43  Construction of Fusion Cell Lines Secreting Antibodies

In order to produce an antibody that specifically binds to the monkey CD43 antigen, a fusion cell line was constructed by the process shown in FIG.

1-1. From the blood of a monkey CD43 Isolation of T Cells

Peripheral blood mononuclear by collecting whole blood from Rhesus Macaqu

cells) were separated. PBMCs were separated by ficoll-gradient centrifugation. The isolated cells were verified by flow cytometry.

1-2. Antigen immunity ( Immunization )

Isolated 6 × 10 PBMC cells were immunized under the following conditions.

Antigen immunity
(Immunization) term Immune pathway amount Marie Immune booster 2 months-1 month-1 months-total 3 times Abdominal cavity 6X 10 ⁵ cells / mouse 5 / each group ODN

1-3. fusion( fusion )

Splenocytes from immunized mice were fused with P3X63Ag8.653 mouse myeloma cells to generate fusion cell lines. Myeloma cells were grown in RPMI medium containing 10% FBS, washed three times with RPMI medium without fetal bovine serum (FBS) before cell fusion, and suspended and checked for cell number. . The splenocytes were removed after the spleens were removed, finely excised, transferred to a tube, left for about 2 minutes, washed three times, and counted. Myeloma cells and myeloma cells were mixed at a ratio of 1: 5, centrifuged, and the supernatant was completely removed. 1 ml of 50% PEG-1500 preheated to 37 ° C. was slowly added over 1 minute, and the tube was gently shaken for 1 minute. Thereafter, 1 ml, 1 ml, and 3 ml of RPMI medium were dropped for 1 minute, and 14 ml were dropped for 2 minutes, gradually diluting. After centrifugation at 1200 rpm for 5 minutes, the supernatant was removed and the pellets of the fused cells were slowly released, followed by RPMI medium containing 1x HAT (20% FBS, hypoxanthine, aminopterin ( Aminopterin) and thymidine) were suspended and dispensed in 200 ul into 96 well culture plates and incubated in a 37 ° C. 5% CO 2 incubator. Seven days after fusion, the medium was changed to HT. After 4-5 days, 150 ~ 200ul of the supernatant was collected from the wells formed by the colonies, and fusion cell lines that specifically reacted to monkey PBMC were selected by flow cytometry.

1-4. Of antibody-producing fusion cells Cloning

A feeder cell culture or a fusion cell medium using celiac macrophage isolated from the abdominal cavity of the mouse was prepared, and the fusion cell line, which was found to produce antibodies, was transferred to 24 wells and cultured. When the cell colonies grew to 50-70%, the culture supernatant was taken to confirm the activity on the monkey PBMC. The highly fused cell line was diluted in HT medium and subjected to limit dilution culture twice or three times. The culture was carried out.

1-5. CD43  antigen Transfectant  Establish

For CD43 antigens, cDNA was transfected in CHO cells to establish a gene transfer infectious agent (transfectant) in which a particular CD antigen was expressed.

Example  2: Immunoprecipitation  Anti monkey through the law CD43  Screening for Affinity Monoclonal Fusion Cell Lines Producing Antibodies

The culture was obtained by culturing the hybridoma obtained for 3 days to select the fusion cell line producing the monkey CD43 specific antibody. CEM7 cells, CD43-expressing T cell-derived leukemia cells, were placed in NP-40 lysis buffer (50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 1% NP-40) to obtain lysate, and antibodies and proteins obtained from hybridomas. Add G bead (Santa Cruz Biotechnologies, Inc., Santa Cruz, Ca, USA) and incubate overnight at 4 degrees. After centrifugation for 3 seconds at 14,000g, 4 degrees, the obtained pellet is put in 20 ul SDS sample buffer and subjected to protein electrophoresis. The results shown in Figure 2 are as shown below.

First, the protein band size of the sample obtained by Western blot with the selected CD43-specific antibody 4-29 (figure 2, lane 2) and immunoprecipitation with 4-29 antibody, and then Western blot with the known CD43 antibody YG5 One protein band size (Fig. 1, lane 1) was found to be about 100 kDa. This is similar to the protein size of the known CD43 antigen. This result was also the same in the samples performed by western blot with 4-29 antibody after immunoprecipitation with the known CD43 antibody YG5 or DFT-1, which was performed in the reverse order of immunoprecipitation and western blot. By identifying proteins of size (Fig. 3, lanes 4 and 4), it was confirmed that 4-29 was an antibody against CD43.

Example  3: of high affinity antibodies CDRs  For cDNA  Sequencing

The main region of the antibody that recognizes a specific epitope of the antigen to form an antigen-antibody complex, the variable region of the heavy chain and light chain, especially the CDR (complementarity determining region) determines the affinity of the complex, the antibody gene obtained through the above example Was cloned to analyze gene sequences for variable regions of the heavy and light chains of the antibody. RNA was extracted from the fusion cell line and RT-PCR was performed using Mouse Ig-Primer set (Novagen, CA, USA). The amplified gene was cloned into a shuttle vector to analyze the nucleotide sequence of the gene. The variable region of heavy chain (VH) of the heavy chain and the variable region of light chain (VL) gene of the light chain variable region were sequenced by substitution with amino acids (see FIG. 3).

Example  4: CD43  Induced increase of T cell activity of antibody

Monkey PBMC was isolated from two monkeys and cultured by mixing ³ × 10 ⁵ cells in 96 well plates and performing Mixed lymphocyte reaction (MLR). At this time, the mouse Igg (1ug / well) as a negative control group CTLA4-Ig (0.5ug / well) to the positive control group and incubated, and the anti-CD43 antibody 0.5ug / well, 1ug / well concentration for 24 hours, Incubated for 48 hours and 72 hours. After culturing at each incubation time, thymidine was added to the wells for 18 hours, and then radioactivity was measured using a beta-counter. As shown in the results of FIG. 4, PBMC proliferation was performed due to the mixed lymphocyte reaction, and especially in the mixed lymphocyte reaction containing the anti-CD43 antibody, cell proliferation was increased by 3.37 times at 48 hours. In contrast, in the mixed lymphocyte reaction with CTLA4-Ig as a negative control, cell proliferation was decreased by about 8 times. This suggests that the antigenic CD43 antibody can enhance the activity of immune cells by 3.37 times or more. R + S: Mixed lymphocyte reaction in which PBMCs obtained from two monkeys are placed in one well of a 96 well plate, each 3X10 ^ 5. Do not add any other antibody. mIgg: control group containing isotype Igg in R + S; CTLA4-Ig: control group containing CTLA4-Ig in R + S; aCD43 (0.5 ug / well): A sample containing 0.5 ug / well of antiCD43 antibody in R + S; aCD43 (1ug / well): A sample containing 1ug / well of antiCD43 antibody in R + S.

Example  5: agionistic CD43  Identification of Antibodies

To confirm that the CD43 antibody is an agonistic antibody, add monkey PBMC (3 X 10 ⁵ / well) and add anti-CD3 antibody (0.25 ug / ml) and anti-CD28 antibody (0.25 ug / ml) for 48 hours. Time incubation. At this time, mIgg (1ug / well) as a negative control group, 30ul of aCD43 hybridoma culture solution as a test group, and purified aCD43 antibody (0.5ug / well) were added thereto. After each incubation time, thymidine was added and cultured for 18 hours, and then radioactivity was measured using a beta-counter. As a result, in the group with the antiCD43 antibody, the proliferation was more than doubled compared to the group without the group (PBMC, mIgg). This suggests that antiCD43 antibody activates T cell proliferation in agonistic form. Abbreviation) PBMC: PBMCs from a single monkey are placed in a well of a 96 well plate, each 3X10 ^ 5, inducing T cell proliferation with antiCD3 and antiCD28 antibodies. Do not add any other antibody. mIgg: control group containing isotype Igg in the PBMC group above; aCD43 soup: a group obtained by obtaining a culture supernatant from a hybridoma secreting antiCD43 antibody and then adding 50ul of the culture solution to the PBMC group; aCD43 (0.5ug / well): A sample containing 0.5ug / well of antiCD43 antibody in the PBMC group.

Korea Cell Line Research Foundation KCLRFBP00231 20100331

<110> SNU R & DB FOUNDATION <120> Monoclonal antibody to specific monkey CD43 and a hybridoma          producing the same <160> 2 <170> Kopatentin 1.71 <210> 1 <211> 130 <212> PRT <213> Mus musculus <400> 1 Leu Asp Phe Leu Val Leu Val Leu Lys Gly Val Leu Cys Glu Val Lys   1 5 10 15 Leu Val Glu Ser Gly Gly Gly Phe Val Gln Pro Gly Gly Ser Leu Lys              20 25 30 Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Asn Thr Tyr Thr Met Ser          35 40 45 Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Tyr Leu      50 55 60 His Lys Gly Ser Gly Asn Thr Tyr Tyr Pro Gly Thr Val Lys Gly Arg  65 70 75 80 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr Leu Gln Met                  85 90 95 Ser Ser Leu Lys Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Leu             100 105 110 Tyr Tyr Ser Pro Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val         115 120 125 Ser Ser     130 <210> 2 <211> 124 <212> PRT <213> Mus musculus <400> 2 Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser   1 5 10 15 Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr              20 25 30 Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu          35 40 45 Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser      50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu  65 70 75 80 Ala Glu Asp Leu Gly Val Phe Phe Cys Ser Gln Ser Thr His Val Pro                  85 90 95 Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala             100 105 110 Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Lys         115 120

Claims (7)

Anti-monkey CD43 monoclonal antibody specific for CD43 antigen isolated from monkey.
The monoclonal antibody according to claim 1, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2.
The monoclonal antibody according to claim 1, wherein the monoclonal antibody is produced by a fusion cell line having an accession number of KCLRF-BP-00231.
A fusion cell line producing the monoclonal antibody of claim 1.
The fusion cell line according to claim 4, wherein the fusion cell line has an accession number of KCLRF-BP-00231.
Any one of claims 1 to 3 wherein the antibody of any one of or a modification to, or mediated by CD43 ⁺ T cells including, composition for the treatment of diseases related to the CD43 ⁺ T cells.
7. The composition of claim 6, wherein the disease is a disease caused by cancer or a viral infection.

Images